Australia's BCAL Diagnostics jumps on partnership with private oncology network
** BCAL Diagnostics BDX.AX jumps 11.1% to A$0.07, highest since June 6 ** Medical equipment supplier enters strategic commercial partnership with Cancer Care Associates, one of Australia's private oncology networks ** Says partnership will accelerate adoption of BREASTEST plus, co's non-invasive blood test that analyses lipids in blood ** BDX falls 35.1% this year, as of last close (Reporting by Sherin Sunny in Bengaluru) ((Sherin.Sunny@thomsonreuters.com;))
Recent news on BCAL Diagnostics
See all newsAustralia's Genetic Signatures urges largest stakeholder to clarify merger intentions; shares rise
Brief: BCAL Diagnostics Introduces Avantect Multi-Cancer Early Detection Test
Brief: BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures
Brief: Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Brief: BCAL To Acquire Shares In Genetic Signatures